Brian I. Rini, MD

Articles

Future Outlooks in the Treatment of Advanced RCC

December 27th 2023

Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.

Data Updates in Advanced RCC from 2023 IKCS: North America

December 27th 2023

Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.

Dr Rini on the FDA Approval of Belzutifan in Advanced RCC

December 21st 2023

Brian I. Rini, MD, FASCO, discusses the significance of the FDA approval of belzutifan for the treatment of patients with advanced renal cell carcinoma

Impact of Treatment Selection and Real-World Outcomes in Advanced RCC

December 20th 2023

Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.

Tackling Toxicity Management in Combination Regimens for Advanced RCC

December 20th 2023

A comprehensive discussion on toxicity management and patient tolerability for combination regimens in the setting of advanced RCC.

CLEAR Trial: Lenvatinib plus Pembrolizumab in Advanced RCC

December 13th 2023

Experts highlight key clinical updates from the CLEAR trial presented at the 2023 IKCS: North America congress, assessing lenvatinib plus pembrolizumab in patients with advanced RCC.

The Evolution of Advanced Renal Cell Carcinoma

December 13th 2023

Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.

Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies

July 17th 2023

Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.

Second-Line Treatment Armamentarium in Clear Cell RCC

July 17th 2023

Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.

Rationale Behind Discontinuing IO Therapy in Clear Cell RCC

July 10th 2023

Focused discussion on the rationale behind discontinuing (or continuing) immunotherapy for patients with advanced clear cell renal cell carcinoma.

Selecting Therapy for a Real-World Patient With Clear Cell RCC

July 10th 2023

Centering discussion on a patient scenario of advanced clear cell renal cell carcinoma, panelists reflect on how they would approach selecting first-line therapy.

Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC

July 3rd 2023

Panelists consider best practices in dosing while managing patients on first-line therapy for advanced clear cell renal cell carcinoma.

Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC

June 26th 2023

A brief discussion on the patient and disease characteristics that help to inform selection of best therapy for patients with advanced clear cell renal cell carcinoma.

Overview of First-Line Combination Therapy in Advanced Clear Cell RCC

June 26th 2023

Key opinion leaders on renal cell carcinoma management review first-line treatment options in the advanced clear cell disease space.

Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC

June 7th 2023

Brian I. Rini, MD, FASCO, discusses long-term survival outcomes in patients with advanced clear cell renal cell carcinoma who received frontline pembrolizumab and axitinib in the phase 3 KEYNOTE-426 trial.

Dr Rini on the OPTIC RCC Trial in Advanced Kidney Cancer

May 19th 2023

Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.

Dr Rini on Retreatment With Immunotherapy Following Progression in RCC

April 11th 2023

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

Dr. Rini on the Current Standard of Care in R/R RCC

February 14th 2023

Brian I. Rini, MD, FASCO, discusses the current treatment landscape for patients with relapsed/refractory renal cell carcinoma.

The Power of No, the Value of Yes

July 14th 2022

Brian I. Rini, MD, and Matthew Tucker, MD, sit down to discuss developing a career path and building a résumé, the value of writing review articles early in fellowship, the power of saying no, and the importance of saying yes.

Dr. Rini on the Results of an Exploratory Analysis of the IMmotion151 Trial in mRCC

May 17th 2021

Brian I. Rini, MD, discusses the results of an exploratory analysis of the phase 3 IMmotion151 trial in metastatic renal cell carcinoma.